News | Radiation Therapy | April 01, 2016

Certifications allow company to continue shipping hyperthermia cancer treatment products throughout the European Union

Pyrexar, ISO, CE mark, certification, European Union, hyperthermia cancer treatment

BSD 2000 hyperthermia system image courtesy of Pyrexar Medical


April 1, 2016 — Pyrexar Medical announced the achievement of ISO 13485 Certification and CE re-certification for its line of hyperthermia products for cancer treatment.

ISO 13485 represents the requirements for a comprehensive quality management system for the design and manufacture of medical devices. The ISO standard is also a required compliance to do business in the European Union.

The CE Mark allows Pyrexar to ship medical devices to any of the 27 member states of the EU.

For more information: www.pyrexar.com


Related Content

News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
Subscribe Now